District Of Columbia is currently home to 920 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
NCT05285891
Recruiting
This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6 and Month 12. At Month 12, participants will be randomized (1:1:1) to one of three Arms with randomized treatm... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
05/13/2024
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Multiple Sclerosis
Register for Updates
A Study of NDI 1150-101 in Patients With Solid Tumors
NCT05128487
Recruiting
This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of NDI-101150 given as monotherapy or in combination with pembrolizumab in adult patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Georgetown University, Washington, District of Columbia
Conditions: Solid Tumor
Register for Updates
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829
Recruiting
A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
Gender:
All
Ages:
1 year and above
Trial Updated:
05/13/2024
Locations: Childrens National Hospital CQTI571A2306, Washington, District of Columbia
Conditions: Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneurona Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Liponeurocytoma, Neurofibromatosis Type 1
Register for Updates
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
NCT05121051
Recruiting
This phase II trial tests whether broccoli seed and sprout extract works to break down cancer causing substances of tobacco in heavy smokers. Smokers are at increased risk for developing lung, head and neck, and other cancers. Broccoli seed and sprout extract may help break down and remove toxic substances caused by tobacco use and possibly produce substances that may protect cells from tobacco smoke-induced damage in current smokers.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/11/2024
Locations: George Washington University Medical Center, Washington, District of Columbia
Conditions: Cigarette Smoking-Related Carcinoma
Register for Updates
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
NCT04530552
Recruiting
Apalutamide is an anti-androgen that blocks the effect of testosterone on prostate cancer growth. This phase IIa trial is designed to determine whether very low doses of apalutamide, given for 3 to 4 weeks before prostate surgery to men with prostate cancer confined to the prostate gland, reduces plasma levels of PSA (a biomarker of apalutamide's ability to block testosterone). If low dose apalutamide lowers PSA levels in this setting, further study of this agent in men with localized prostate c... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
05/11/2024
Locations: George Washington University Medical Center, Washington, District of Columbia
Conditions: Prostate Adenocarcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Register for Updates
Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy
NCT05747794
Recruiting
The goal of this clinical trial is to compare the safety and efficacy of eftilagimod alpha (efti) in combination with paclitaxel standard of care chemotherapy in participants with metastatic breast cancer. The main questions it aims to answer are: What is the optimal biological dose (OBD) of efti in combination with weekly paclitaxel chemotherapy? Can efti combined with weekly paclitaxel chemotherapy prolong overall survival in participants with metastatic breast cancer if compared to weekly p... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2024
Locations: The George Washington University Cancer Center, Washington, District of Columbia
Conditions: Breast Carcinoma
Register for Updates
Uncontrolled Hypertension Among the Homeless
NCT05187013
Recruiting
This study is designed to assess the effect of implementing a mobile health (mHealth) strategy using text messaging for hypertension (HTN) management among hypertensive homeless persons with uncontrolled blood pressure age 21 or older in shelter-clinics in New York City (NYC). The study uses a randomized clinical trial design (homeless, n=120) and semi-structured interviews (homeless, n=30; providers, n=20). The control group will receive text messages for usual standard care/healthy lifestyle... Read More
Gender:
All
Ages:
21 years and above
Trial Updated:
05/10/2024
Locations: George Washington University, Washington, District of Columbia
Conditions: Hypertension
Register for Updates
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
NCT04655404
Recruiting
This is a pilot study that will evaluate disease status in children that have been newly diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the medication (Larotrectinib) have been given. The study will also evaluate the safety of larotrectinib when given with chemotherapy in your children; as well as the safety larotrectinib when given post-focal radiation therapy.
Gender:
All
Ages:
21 years and below
Trial Updated:
05/10/2024
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Register for Updates
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
NCT03674307
Recruiting
The Canadian Australasian Randomized Trial of Screening Kidney Transplant Candidates for Coronary Artery Disease (CARSK) will test the hypothesis that eliminating the regular use of non-invasive screening tests for CAD AFTER waitlist activation is not inferior to regular (i.e., annual) screening for CAD during wait-listing for the prevention of Major Adverse Cardiac Events. Secondary analyses will assess the impact of screening on the rate of transplantation, and the relative cost-effectiveness... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2024
Locations: The George Washington University, Washington, District of Columbia
Conditions: Cardiovascular Diseases, End Stage Renal Disease, Kidney Transplantation, Dialysis Related Complication
Register for Updates
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
NCT06272487
Recruiting
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Clinical Trial Site, Washington, District of Columbia
Conditions: High Cardiovascular Risk, Hypertension
Register for Updates
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
NCT06095505
Recruiting
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib in patients with pathologically-confirmed extensive-stage small cell lung cancer (ES-SCLC) following progression on or after first-line treatment with platinum-based chemotherapy along with an anti-PDL-1 immunotherapy agent. This study is intended to evaluate the efficacy, safety, and pharmacokinetics of alisertib and to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Georgetown Lombardi Cancer Center, Washington, District of Columbia
Conditions: Small Cell Lung Cancer
Register for Updates
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450
Recruiting
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Research Site, Washington, District of Columbia
Conditions: Viral Lung Infection and Acute Respiratory Failure
Register for Updates